Results 41 to 50 of about 6,218 (156)

From prediction to intervention: Paradigm shifts in causal AI for precision medicine and large‐scale cohorts

VIEW, Volume 7, Issue 4, August 2026.
Large‐scale cohorts and multimodal biomedical data have enabled powerful predictive models for clinical risk stratification, but prediction alone cannot guide effective interventions. This review introduces causal artificial intelligence as a design‐first framework that integrates target trial emulation, causal discovery, and robust effect estimation ...
Linlin Cao, Yudian Xu, Yifan Chen, Honghao Huang, Wei Xu, Jun Pu   +5 more
wiley   +1 more source

Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study

BMC Infectious Diseases
Background and aim Two oral antivirals (Nirmatrelvir- ritonavir and Azvudine) are widely used in China practice during the Omicron wave of the pandemic.
Xiaobo Han, Darui Gao, Chenglong Li, Xin Yuan, Junchang Cui, Weiguo Zhao, Fei Xie, Kaifei Wang, Yuhong Liu, Guoxin Muo, Na Xi, Mengli Zheng, Rentao Wang, Kun Xiao, Dahui Zhao, Xinxin Zhang, Xinjie Han, Bo Wang, Tiantian Zhang, Wuxiang Xie, Lixin Xie   +20 more
doaj   +1 more source

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study

Annals of Medicine
Background Immunocompromised patients are at high risk of developing persisting/prolonged COVID-19. Data on the early combined use of antivirals and monoclonal antibodies in this population are scarce.Research design and methods We performed an ...
I. Gentile, G. Viceconte, F. Cuccurullo, D. Pietroluongo, A. D’Agostino, M. Silvitelli, S. Mercinelli, R. Scotto, F. Grimaldi, S. Palmieri, A. Gravetti, F. Trastulli, M. Moccia, A. R. Buonomo   +13 more
doaj   +1 more source

Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insight

Frontiers in Pharmacology
The clinical drug-drug interaction side-effects of Ritonavir, an ingredient in Paxlovid™, have been documented, highlighting the need to explore alternative administration methods for Nirmatrelvir, another drug in the Paxlovid™ combination. In this study,
Giang H. Ta, Max K. Leong
doaj   +1 more source

Nirmatrelvir-ritonavir for COVID-19 [PDF]

Canadian Medical Association Journal, 2022
McDonald, Emily G, Lee, Todd C
openaire   +2 more sources

Bridging the Pregnancy Knowledge Gap: A Real‐World Analysis of Medication Use and Drug–Drug Interaction Risk in Crohn's Disease and Multiple Sclerosis

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT The exclusion of pregnant individuals from clinical trials has resulted in a significant medical knowledge gap for this population. Leveraging real‐world data (RWD) provides a critical window into the prevalence and use of medications during pregnancy.
Jacqueline Williams, Rucha Sane, Amita Joshi, Kit Wun Kathy Cheung, Bianca Vora   +4 more
wiley   +1 more source

Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong

Emerging Infectious Diseases
We compared the effectiveness and interactions of molnupiravir and nirmatrelvir/ritonavir and 2 vaccines, CoronaVac and Comirnaty, in a large population of inpatients with COVID-19 in Hong Kong. Both the oral antiviral drugs and vaccines were associated
Yue Yat Harrison Cheung, Eric Ho Yin Lau, Guosheng Yin, Yun Lin, Benjamin J. Cowling, Kwok Fai Lam   +5 more
doaj   +1 more source

Population pharmacokinetic/pharmacodynamic modelling to evaluate favipiravir in combination with lopinavir–ritonavir in patients with COVID‐19

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2390-2402, July 2026.
Aims The repurposed use of favipiravir in COVID‐19 has been reported to have limited clinical efficacy, yet it has been widely used in some countries. Favipiravir causes mutagenesis in RNA viruses, and it is currently unknown whether it may have a measurable effect on the virus in humans.
Akosua A. Agyeman, Laura Buggiotti, Li‐An K. Brown, Jose A. Guerra‐Assuncao, Japhette E. Kembou‐Ringert, Wen Y. Mak, Judith Breuer, David M. Lowe, Joseph F. Standing, FLARE Investigators   +9 more
wiley   +1 more source

Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions

Infectious Diseases and Therapy
Introduction Although real-world studies demonstrate that those prescribed nirmatrelvir/ritonavir (and particularly within 5 days of symptom onset) are less likely to experience severe COVID-19 outcomes, prior studies show that only a small fraction of ...
Abby E. Rudolph, Farid L. Khan, Tanya G. Singh, Srinivas Rao Valluri, Laura A. Puzniak, John M. McLaughlin   +5 more
doaj   +1 more source

ACE2‐ and HR2‐Mimetic Peptides Inhibit Replication of Two SARS‐CoV‐2 Variants

Journal of Medical Virology, Volume 98, Issue 7, July 2026.
ABSTRACT Several therapeutic approaches to inhibiting severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) focus on blocking the virus's entry mechanism. This can be blocked in two ways: by interacting with the receptor‐binding domain (RBD) of the spike protein and human angiotensin‐converting enzyme 2 (ACE2), and by blocking viral‐cellular ...
Melvin E. Zúñiga‐Hernández, Karen L. Reyes‐Barrera, Sergio N. Hidalgo‐Figueroa, Edgar D. Páez‐Pérez, Clara I. Espitia Pinzón, Ángel G. Alpuche‐Solís   +5 more
wiley   +1 more source